Research Progress on the Effect of Adenomyosis on Endometrial Cancer and Related Mechanisms

doi:10.12280/gjfckx.20200850

Abstract

Abstract:

Endometrial cancer is one of the most common gynecological malignancies, and adenomyosis is also a common benign gynecological disease, with unknown etiology. Adenomyosis and endometrial cancer are not only two independent gynecological diseases, but also have intricate connections. From the epidemiological and clinicopathological characteristics,adenomyosis may be a risk factor for endometrial cancer, but it is also a protective factor to inhibit the progression of endometrial cancer. From the pathogenesis, the two disease have common mechanisms on molecular signaling pathways, effects of estrogen and its receptors, and mismatch repair gene deficiency, and because of the molecular and mechanical blocking effects of adenomyosis on endometrial cancer, the progression of endometrial cancer is hindered. Clarifying the relationship between the two and the corresponding mechanism will contribute to the accurate clinical diagnosis and follow-up of endometrial cancer and adenomyosis, and improve the effect of diagnosis and treatment.

Key words: Endometrial neoplasms, Adenomyosis, Estrogens, Receptors,estrogen, DNA mismatch repair

GUO Zheng-chen, DUAN Hua, WANG Sha. Research Progress on the Effect of Adenomyosis on Endometrial Cancer and Related Mechanisms[J]. Journal of International Obstetrics and Gynecology, 2021, 48(3): 343-346.

References 35

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020,70(1):7-30. doi: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. doi: 10.3322/caac.21338. doi: 10.3322/caac.21338
[3]	段华. 中国妇科内镜诊疗技术从弱到强并跑国际之路[J]. 中国计划生育和妇产科, 2019,11(10):3-6,9. doi: 10.3969/j.issn.1674-4020.2019.10.01. doi: 10.3969/j.issn.1674-4020.2019.10.01
[4]	Khalifa MA, Atri M, Klein ME, et al. Adenomyosis As a Confounder to Accurate Endometrial Cancer Staging[J]. Semin Ultrasound CT MR, 2019,40(4):358-363. doi: 10.1053/j.sult.2019.04.004. doi: 10.1053/j.sult.2019.04.004
[5]	Musa F, Frey MK, Im HB, et al. Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium?[J]. Am J Obstet Gynecol, 2012, 207(5):417.e1-6. doi: 10.1016/j.ajog.2012.06.051. doi: 10.1016/j.ajog.2012.06.051
[6]	Shen F, Liu Y, Lin L, et al. Association of benign gynaecological diseases and risk of endometrial and ovarian cancers[J]. J Cancer, 2020,11(11):3186-3191. doi: 10.7150/jca.39626. doi: 10.7150/jca.39626
[7]	Yeh CC, Su FH, Tzeng CR, et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study[J]. PLoS One, 2018,13(3):e0194011. doi: 10.1371/journal.pone.0194011. doi: 10.1371/journal.pone.0194011
[8]	Kok VC, Tsai HJ, Su CF, et al. The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis: A Population-Based Study[J]. Int J Gynecol Cancer, 2015,25(6):968-976. doi: 10.1097/IGC.0000000000000454. doi: 10.1097/IGC.0000000000000454
[9]	Taneichi A, Fujiwara H, Takahashi Y, et al. Influences of uterine adenomyosis on muscle invasion and prognosis of endometrioid adenocarcinoma[J]. Int J Gynecol Cancer, 2014,24(8):1429-1433. doi: 10.1097/IGC.0000000000000243. doi: 10.1097/IGC.0000000000000243
[10]	Gizzo S, Patrelli TS, Dallasta A, et al. Coexistence of adenomyosis and endometrioid endometrial cancer: Role in surgical guidance and prognosis estimation[J]. Oncol Lett, 2016,11(2):1213-1219. doi: 10.3892/ol.2015.4032. doi: 10.3892/ol.2015.4032
[11]	Johnatty SE, Stewart C, Smith D, et al. Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer[J]. Sci Rep, 2020,10(1):3621. doi: 10.1038/s41598-020-59916-1. doi: 10.1038/s41598-020-59916-1
[12]	谢玲玲, 林荣春, 林仲秋. 《2020NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020,36(4):333-339. doi: 10.19538/j.fk2020040112. doi: 10.19538/j.fk2020040112
[13]	Hertlein L, Rath J, Zeder-Göss C, et al. Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only[J]. Oncol Lett, 2017,14(3):3302-3308. doi: 10.3892/ol.2017.6592. doi: 10.3892/ol.2017.6592 pmid: 28927080
[14]	Matsuo K, Cahoon SS, Gualtieri M, et al. Significance of adenomyosis on tumor progression and survival outcome of endometrial cancer[J]. Ann Surg Oncol, 2014,21(13):4246-4255. doi: 10.1245/s10434-014-3880-6. doi: 10.1245/s10434-014-3880-6
[15]	Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms[J]. Reprod Biomed Online, 2017,35(5):592-601. doi: 10.1016/j.rbmo.2017.06.016. doi: 10.1016/j.rbmo.2017.06.016
[16]	Harmsen MJ, Wong C, Mijatovic V, et al. Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review[J]. Hum Reprod Update, 2019,25(5):647-671. doi: 10.1093/humupd/dmz024. doi: 10.1093/humupd/dmz024
[17]	García-Solares J, Donnez J, Donnez O, et al. Pathogenesis of uterine adenomyosis: invagination or metaplasia?[J]. Fertil Steril, 2018,109(3):371-379. doi: 10.1016/j.fertnstert.2017.12.030. doi: 10.1016/j.fertnstert.2017.12.030
[18]	Guo F, Zhang H, Jia Z, et al. Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer[J]. Am J Cancer Res, 2018,8(7):1317-1331.
[19]	Streuli I, Santulli P, Chouzenoux S, et al. Activation of the MAPK/ERK Cell-Signaling Pathway in Uterine Smooth Muscle Cells of Women With Adenomyosis[J]. Reprod Sci, 2015,22(12):1549-1560. doi: 10.1177/1933719115589410. doi: 10.1177/1933719115589410
[20]	Liu A, Zhang D, Yang X, et al. Estrogen receptor alpha activates MAPK signaling pathway to promote the development of endometrial cancer[J]. J Cell Biochem, 2019,120(10):17593-17601. doi: 10.1002/jcb.29027. doi: 10.1002/jcb.29027
[21]	Mu L, Chen W, Ma Y, et al. Expression of focal adhesion kinase in the eutopic endometrium of women with adenomyosis varies with dysmenorrhea and pelvic pain[J]. Exp Ther Med, 2015,10(5):1903-1907. doi: 10.3892/etm.2015.2736. doi: 10.3892/etm.2015.2736
[22]	Xu Y, Li Y, Pan J, et al. EM2D9, A monoclonal antibody against integrin α5β1, has potent antitumor activity on endometrial cancer in vitro and in vivo[J]. Cancer Lett, 2020,483:66-74. doi: 10.1016/j.canlet.2020.02.019. doi: 10.1016/j.canlet.2020.02.019
[23]	Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: an update on molecular mechanisms[J]. Reprod Biomed Online, 2017,35(5):592-601. doi: 10.1016/j.rbmo.2017.06.016. doi: 10.1016/j.rbmo.2017.06.016
[24]	Rodriguez AC, Blanchard Z, Maurer KA, et al. Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions[J]. Horm Cancer, 2019,10(2/3):51-63. doi: 10.1007/s12672-019-0358-9. doi: 10.1007/s12672-019-0358-9
[25]	Sun FQ, Duan H, Wang S, et al. 17β-Estradiol Induces Overproliferation in Adenomyotic Human Uterine Smooth Muscle Cells of the Junctional Zone Through Hyperactivation of the Estrogen Receptor-Enhanced RhoA/ROCK Signaling Pathway[J]. Reprod Sci, 2015,22(11):1436-1444. doi: 10.1177/1933719115584447. doi: 10.1177/1933719115584447
[26]	Wilkenfeld SR, Lin C, Frigo DE. Communication between genomic and non-genomic signaling events coordinate steroid hormone actions[J]. Steroids, 2018,133:2-7. doi: 10.1016/j.steroids.2017. 11.005. doi: S0039-128X(17)30215-5 pmid: 29155216
[27]	Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013,497(7447):67-73. doi: 10.1038/nature12113. doi: 10.1038/nature12113 pmid: 23636398
[28]	Goumenou AG, Arvanitis DA, Matalliotakis IM, et al. Loss of heterozygosity in adenomyosis on hMSH2, hMLH1, p16Ink4 and GALT loci[J]. Int J Mol Med, 2000,6(6):667-671. doi: 10.3892/ijmm.6.6.667. doi: 10.3892/ijmm.6.6.667 pmid: 11078826
[29]	沈雪, 段华. 子宫腺肌病病因及发病机制研究新观点[J]. 中国计划生育和妇产科, 2019,11(4):3-6. doi: 10.3969/j.issn.1674-4020.2019.04.01. doi: 10.3969/j.issn.1674-4020.2019.04.01
[30]	Sotnikova N, Antsiferova I, Malyshkina A. Cytokine network of eutopic and ectopic endometrium in women with adenomyosis[J]. Am J Reprod Immunol, 2002,47(4):251-255. doi: 10.1034/j.1600-0897.2002.01040.x. doi: 10.1034/j.1600-0897.2002.01040.x pmid: 12069392
[31]	Zitvogel L, Kepp O, Galluzzi L, et al. Inflammasomes in carcinogenesis and anticancer immune responses[J]. Nat Immunol, 2012,13(4):343-351. doi: 10.1038/ni.2224. doi: 10.1038/ni.2224
[32]	David JM, Dominguez C, Hamilton DH, et al. The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance[J]. Vaccines (Basel), 2016,4(3):22. doi: 10.3390/vaccines4030022. doi: 10.3390/vaccines4030022
[33]	Li J, Yanyan M, Mu L, et al. The expression of Bcl-2 in adenomyosis and its effect on proliferation, migration, and apoptosis of endometrial stromal cells[J]. Pathol Res Pract, 2019,215(8):152477. doi: 10.1016/j.prp.2019.152477. doi: 10.1016/j.prp.2019.152477
[34]	Shen M, Liu X, Zhang H, et al. Transforming growth factor A1 signaling coincides with epithelial mesenchymal transition and fibroblast to myofibroblast transdifferentiation in the development of adenomyosis in mice[J] Hum Reprod, 2016,31(2):355-369. doi: 10.1093/humrep/dev314. doi: 10.1093/humrep/dev314
[35]	杨惠娟, 于婷, 韩旭. 子宫腺肌病诊治及其与子宫内膜癌关系的研究进展[J]. 国际妇产科学杂志, 2020,47(2):212-216. doi: 10.3969/j.issn.1674-1870.2020.02.023. doi: 10.3969/j.issn.1674-1870.2020.02.023